



SUMMER MDS UPDATE

Hybrid Patient & Family Conferences

Empowering Every Patient

Join Us!

Buffalo, NY

September 10, 2022

Registration for this conference is available! Click [here](#) to register for in-person and virtual attendance.



Miami, FL

October 29, 2022

Registration for this conference is available! Click [here](#) to register for in-person and virtual attendance.



INFORMATION

Patient stories provide hope and support to others diagnosed the MDS. In this patient panel discussion, hear how Joan Powell and Maureen Ratliff have battled MDS.

Click [here](#) to tune in.

If you would like to share your story, please contact us, help@aamds.org.



IMPORTANT CLINICAL TRIALS

Please consult your health care provider about enrolling in clinical trials. For a full description of each trial, please visit www.aamds.org/treatments/clinical-trials.

A STUDY OF APG-2575 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and pharmacokinetics (PK) of APG-2575 in combination with azacitidine in the patients with AML or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II). Full details are available [here](#).

A STUDY OF APG-115 ALONE OR COMBINED WITH AZACITIDINE IN PATIENTS WITH AML, CMML, OR MDS

This is a two-part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + azacitidine in Part 2. Full details are available [here](#).

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any clinical trial listed on our website. Pharmaceutical company sponsored content is highlighted only to give additional information about the trial. All trials are listed on <https://clinicaltrials.gov/>

MDS Related Research

■ Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS

Jennifer J. Trowbridge, Daniel T. Starczynowski

There is an imminent need to develop new therapeutic strategies to ameliorate disorders of hematopoietic aging, including clonal hematopoiesis and myelodysplastic syndrome (MDS). Cell-intrinsic dysregulation of innate immune- and inflammatory-related pathways as well as systemic inflammation have been implicated in hematopoietic defects associated with aging, clonal hematopoiesis, and MDS. Read more [here](#).

■ Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

Elihu Estey, Robert P. Hasserjian, Hartmut Dohner

Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with myelodysplastic syndrome (MDS). Although less intense therapies are being used more often in AML, the dichotomy between AML and MDS remains, with the presence of $\geq 20\%$ myeloblasts in marrow or peripheral blood generally regarded as defining AML. Read more [here](#).

Need help? Please contact us:

Email us at help@aamds.org or call 301-279-7202

UPCOMING EVENTS

MDS WEBINARS FOR PATIENTS AND CAREGIVERS

AAMDSIF offers free live (and on-demand) webinars for patients and caregivers. A full listing of available webinars can be found on our website (<https://www.aamds.org/education/courses>). Send your suggested topics to help@aamds.org!


Ask the Transplant Expert



Genetic Testing for Bone Marrow Failure Diseases




VEXAS Syndrome (On-Demand)



AAMDSIF MDS SUPPORT GROUPS

AAMDSIF hosts virtual support groups for MDS patients, family members and caregivers. Our support groups are posted on our website and we encourage you to join these upcoming opportunities to connect:



MARCH for MARROW
AA-MDS INTERNATIONAL FOUNDATION

Find a March for Marrow Event Near You



[Detroit - August 28, 2022](#)

[Virginia - September 18, 2022](#)

[New Jersey - September 25, 2022](#)

[Nevada - October 15, 2022](#)